U.S. Interactive Media and Services Stock News

NYSE:ALK
NYSE:ALKAirlines

How Investors Are Reacting To Alaska Air Group (ALK) Winning a Single Operating Certificate with Hawaiian

In recent weeks, Alaska Air Group secured a single operating certificate for Alaska Airlines and Hawaiian Airlines, while analysts highlighted its stronger-than-expected earnings, improved cost control, and operational discipline. This combination of operational progress and favorable analyst commentary has supported a more constructive view of Alaska Air Group’s earnings potential and business resilience, even as the airline industry remains cyclical and exposed to cost and demand...
NasdaqGS:PDFS
NasdaqGS:PDFSSemiconductor

Assessing PDF Solutions (PDFS) Valuation After Brown Capital’s AI And Semiconductor Supply Chain Bet

PDF Solutions (PDFS) is back on radar after the Brown Capital Management Small Company Fund added the stock in Q4 2025, citing its AI-focused analytics and semiconductor supply chain solutions as key attractions. See our latest analysis for PDF Solutions. At a share price of US$33.78, PDF Solutions has seen a 24.65% 90 day share price return and a 50.00% 1 year total shareholder return, suggesting momentum has picked up as investors respond to its AI and semiconductor supply chain story. If...
NasdaqGS:TWST
NasdaqGS:TWSTBiotechs

Assessing Twist Bioscience (TWST) Valuation After New Invenra Bispecific Antibody Licensing Deal

Twist Bioscience (TWST) is back in focus after announcing a licensing deal with Invenra that brings the B-Body bispecific antibody platform under a co-exclusive arrangement, directly expanding Twist’s antibody discovery service offering. See our latest analysis for Twist Bioscience. The licensing news lands after a strong run, with the latest share price at $46.92, a 30 day share price return of 11.69% and a 90 day share price return of 46.58%. Looking further out, the stock shows a 1 year...
NasdaqCM:PVLA
NasdaqCM:PVLABiotechs

Is Palvella Therapeutics (PVLA) Still Attractive After A 7x One-Year Surge In Price?

If you are wondering whether Palvella Therapeutics at around US$135 is still offering value after a strong run, this article focuses squarely on what the current price might be implying. The stock has moved sharply recently, with a 57.6% return over the last 7 days, 71.5% over 30 days, and 34.6% year to date, while the 1 year return is very large at close to 7x. These moves sit against a backdrop of heightened interest in Palvella Therapeutics, including investor attention around its listing...
NasdaqGS:SPSC
NasdaqGS:SPSCSoftware

SPS Commerce Earnings Beat Meets Insider Selling And Growth Concerns

SPS Commerce (NasdaqGS:SPSC) reported earnings per share that were ahead of expectations, highlighting resilient profitability. Shortly after the results, the CEO sold company shares, drawing attention to insider activity. Craig Hallum downgraded the stock, citing a revenue miss and a softer outlook for 2026. SPS Commerce focuses on cloud based supply chain and retail data services, giving retailers and suppliers tools to manage orders and product information. That positions the company in...
NYSE:MTD
NYSE:MTDLife Sciences

Is Mettler-Toledo (MTD) Pricing Reflect Its Precision Instruments Strength After Recent Pullback

If you are wondering whether Mettler-Toledo International remains a quality business at the current price or if the market has moved ahead of the fundamentals, this article will walk you through what the valuation signals are really saying. The stock last closed at US$1,366.69, with a 7 day return showing a 0.8% decline, a 30 day return showing a 2.5% decline, and a 1 year return of 7.4%. Taken together, this offers a mixed picture of recent sentiment and longer term performance. Recent news...
NYSE:LVS
NYSE:LVSHospitality

Las Vegas Sands Backs UNLV Girls STEM Camp As Valuation Questions Linger

Las Vegas Sands (NYSE:LVS) is supporting the UNLV STEM for Girls Camp, aimed at encouraging girls to pursue science, technology, engineering and math fields. The initiative focuses on expanding access to STEM education for young women in the company’s home region. This support highlights the company’s focus on social responsibility and workforce diversity alongside its core resort and gaming operations. For investors watching Las Vegas Sands at a current share price of $56.72, this new...
NYSE:WCC
NYSE:WCCTrade Distributors

Assessing Wesco International’s Valuation After US$1.5b Senior Notes Offering And Refinancing Steps

WESCO International (WCC) has drawn fresh attention after completing a US$1.5b private offering of unsecured senior notes, using the proceeds to redeem 7.250% notes due 2028 and repay portions of existing credit facilities. See our latest analysis for WESCO International. Despite the fresh financing news and a higher quarterly dividend, the 1-day share price return of 2.14% and 7-day share price return of 2.52% show near term pressure. In contrast, a 90-day share price return of 8.26% and...
NasdaqGS:STRL
NasdaqGS:STRLConstruction

Is It Too Late To Consider Sterling Infrastructure (STRL) After A Huge Five Year Run?

If you are wondering whether Sterling Infrastructure's share price still offers value after a strong run, this article will walk through how that question stacks up against the numbers. The stock recently closed at US$428.13, with returns of 14.6% over the last 30 days, 34.1% year to date, 236.6% over 1 year and a very large gain over 5 years. Recent coverage of Sterling Infrastructure has focused on its role in capital projects and how investor attention has shifted toward companies...
NasdaqGS:MORN
NasdaqGS:MORNCapital Markets

Morningstar Expands Retirement Reach And Data Platform With New Leadership

Morningstar (NasdaqGS:MORN) has launched Foundation Series Collective Investment Trusts in collaboration with Alta Trust Company and several large asset managers. The new CITs focus on providing retirement plans with broader access to institutional investment solutions with an emphasis on simplicity and diversification. Morningstar has also appointed Scott Brown as President of Direct Platform, with a remit to accelerate product development and data platform work. Morningstar, known for its...
NYSE:PACS
NYSE:PACSHealthcare

PACS Group (PACS) Margin Jump To 3.6% Tests Rich 29.9x P/E Narrative

PACS Group (PACS) just wrapped up FY 2025 with Q4 revenue of US$1.4b and basic EPS of US$0.38, supported by trailing twelve month revenue of US$5.3b and EPS of US$1.23 that has been tied to very large year on year earnings growth of 243.5%. Over recent periods, the company has seen quarterly revenue move from US$1.21b in Q4 2024 to US$1.36b in Q4 2025, while quarterly EPS went from US$0.24 to US$0.38. This sets up a results season where strong reported earnings growth, margin improvement to...
NasdaqGS:WGS
NasdaqGS:WGSHealthcare

COO Share Sale Highlights GeneDx Valuation Gap And Recent Stock Pressure

GeneDx Holdings (NasdaqGS:WGS) Chief Operating Officer Bryan Dechairo has sold his entire direct shareholding in an open market transaction. The sale was executed under a Rule 10b5-1 trading plan and leaves Dechairo with no direct equity interest in the company. This insider transaction comes as GeneDx continues to report business growth and operational progress. The move comes at a time when GeneDx shares last closed at $79.71, with the stock showing mixed performance across time frames...
NasdaqGS:WBD
NasdaqGS:WBDEntertainment

Warner Bros. Discovery (WBD) One Off US$2.4b Gain Tests Bullish Profitability Narratives

Warner Bros. Discovery (WBD) has capped FY 2025 with fourth quarter revenue of US$9.5b and a basic EPS loss of US$0.10, setting the tone for a year where profitability on a trailing basis has been supported by a sizeable one off gain. The company has seen quarterly revenue range between US$9.0b and US$9.8b across 2025, with EPS swinging from a loss of US$0.18 in Q1 to a profit of US$0.64 in Q2 before reverting to losses in Q3 and Q4. This leaves investors focusing on how much of the reported...
NasdaqGS:BTSG
NasdaqGS:BTSGHealthcare

BrightSpring Health Services (BTSG) EPS Jump In Q4 2025 Tests Bullish Profitability Narrative

BrightSpring Health Services (BTSG) just closed FY 2025 with fourth quarter revenue of US$3.6b and basic EPS of US$0.24, while net income from continuing operations, excluding extra items, came in at US$49.3m. The company has seen quarterly revenue move from US$3.1b and EPS of US$0.08 in Q4 2024 to US$3.6b and EPS of US$0.24 in Q4 2025, with trailing twelve month EPS at US$0.53 and net income of US$106.3m on US$12.9b in revenue. This puts the latest report firmly in focus for anyone tracking...
NYSE:ESAB
NYSE:ESABMachinery

ESAB Ruffian Launch And Linde Tie Up Put Valuation In Focus

ESAB (NYSE:ESAB) has introduced the Ruffian EMP 270G engine-driven welding generator at CONEXPO-CON/AGG 2026. The unit features advanced inverter technology and more than 100 customer-requested features. The product was developed in collaboration with Linde, with exclusive offerings tied to the trade show launch. ESAB, listed on the NYSE under the ticker ESAB, is a welding and cutting equipment company with a focus on industrial and construction applications. By rolling out the Ruffian EMP...
NYSE:ECL
NYSE:ECLChemicals

How Investors Are Reacting To Ecolab (ECL) Co-COO Reshuffle And New Debt Shelf Registration

Earlier this month, Ecolab’s board reshaped its senior team by adding the President title to Chairman and CEO Christophe Beck and splitting the chief operating officer role between Darrell R. Brown as Co-COO – Global Markets and Gregory B. Cook as Co-COO – Global Businesses, while director Victoria J. Reich decided not to stand for re-election and the company affirmed its US$0.73 quarterly dividend. These leadership changes, alongside a new shelf registration for debt securities, suggest...
NasdaqGM:AAOI
NasdaqGM:AAOICommunications

Applied Optoelectronics (AAOI) Narrower Q4 Loss Tests Bullish Earnings Ramp Narrative

Applied Optoelectronics (AAOI) closed out FY 2025 with fourth quarter revenue of US$134.3 million and a basic EPS loss of US$0.03, alongside net income excluding extra items of a US$2.0 million loss. This puts the focus squarely on how efficiently that top line is being converted into earnings. The company has seen quarterly revenue move from US$65.2 million in Q3 2024 to US$100.3 million in Q4 2024, then to US$99.9 million in Q1 2025, US$103.0 million in Q2 2025, US$118.6 million in Q3 2025...
NasdaqGS:PWP
NasdaqGS:PWPCapital Markets

Is Perella Weinberg (PWP) Quietly Redefining Earnings Resilience Despite a Modest Revenue Decline?

Perella Weinberg Partners recently reported quarterly revenues of US$219.2 million, a 2.9% year-on-year decline that still exceeded analyst estimates by a very large margin, alongside an earnings beat. The results highlight how the firm’s operational execution outpaced expectations even as headline revenue slipped, offering a more nuanced picture of performance for investors. Next, we’ll examine how this better-than-expected revenue performance shapes Perella Weinberg Partners’ investment...
NasdaqGS:CTBI
NasdaqGS:CTBIBanks

Is Community Trust Bancorp’s (CTBI) Steady Dividend Growth Reframing Its Core Earnings Story?

Community Trust Bancorp recently highlighted a quarterly dividend of US$0.53 per share, implying a 3.43% yield and reflecting five consecutive years of annual dividend increases averaging 5.32%. Alongside this dividend profile, the company is guided by a Zacks Consensus Estimate pointing to fiscal 2026 earnings of US$5.79 per share, suggesting investors are closely watching how income and earnings trends align. With this backdrop of consistent dividend growth, we’ll examine how the company’s...
NasdaqGM:STAA
NasdaqGM:STAAMedical Equipment

STAAR Surgical (STAA) Is Up 12.0% After FDA Expands EVO ICL Age Range to 60 – Has The Bull Case Changed?

In February 2026, STAAR Surgical announced that the FDA approved an expanded age indication for its EVO/EVO+ Visian Implantable Collamer Lenses, extending U.S. use from ages 21–45 to 21–60 following three-year safety data. This broader label meaningfully enlarges the potential U.S. candidate pool for EVO ICL, especially among adults aged 46–60 who were previously excluded. We’ll now examine how opening EVO ICL access to patients up to age 60 could reshape STAAR Surgical’s longer-term...
NYSE:DOC
NYSE:DOCHealth Care REITs

A Look At Healthpeak Properties (DOC) Valuation As CEO Prepares For Citi Conference And Janus Living IPO

Healthpeak Properties (DOC) is in focus after confirming that CEO Scott Brinker will speak at the Citi 2026 Global Property CEO Conference, while the company continues work on the Janus Living senior housing REIT IPO. See our latest analysis for Healthpeak Properties. Recent interest around the CEO’s Citi conference appearance and the Janus Living IPO work comes as the stock shows a 1-day share price return of 0.97% and a 7-day share price return of 4.06%. The 1-year total shareholder return...
NYSE:CPNG
NYSE:CPNGMultiline Retail

Coupang (CPNG) Q4 Loss Highlights Fragile Margins Behind Bullish Earnings Narratives

Coupang FY 2025 Results Set Up a Mixed but Margin Focused Story Coupang (CPNG) closed FY 2025 with fourth quarter revenue of US$8.8b and a basic EPS loss of US$0.01, as net income excluding extra items came in at a US$26m loss against a backdrop of growing full year scale. The company has seen quarterly revenue step up from US$7.9b in Q4 2024 to between US$7.9b and US$9.3b through 2025. Basic EPS has moved between a profit of US$0.06 and a small loss in the latest quarter, setting up a TTM...
NasdaqGS:NVMI
NasdaqGS:NVMISemiconductor

Is Nova (NVMI) Pricing In Too Much Growth After Recent Semiconductor Rerating?

If you are wondering whether Nova's share price still reflects good value after a strong run, this article is for you. We will walk through what the current market price might be implying about the business. Nova's stock last closed at US$438.86, with a 7 day return of a 0.5% decline, a 30 day return of a 9.9% decline, a year to date return of 26.3% and a 1 year return of 83.5%, while the 3 year return is very large and the 5 year return is also very large. Recent news coverage around Nova...
NasdaqGS:OPRA
NasdaqGS:OPRASoftware

Opera (OPRA) One Off Gain Clouds Strong FY 2025 Profit Growth Narrative

Opera (NasdaqGS:OPRA) posts FY 2025 results Opera (NasdaqGS:OPRA) closed out FY 2025 with fourth quarter revenue of US$176.7 million and basic EPS of US$0.62, rounding off a trailing twelve month run of US$614.4 million in revenue and EPS of US$1.21 as earnings grew 34.1% over the past year. The company has seen revenue move from US$480.6 million on a trailing basis at the end of 2024 to US$614.4 million by the end of 2025, while trailing net profit margin edged up from 16.8% to 17.6%. With...